Publication: Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover
3
item.page.dc.date.issued
1998-05-05
item.page.dc.type
item.page.dc.identifier.issn
0171967X
item.page.dc.identifier.doi
item.page.dc.identifier.other
2-s2.0-0031894837
item.page.dc.rights
Mahidol University
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Calcified Tissue International. Vol.62, No.5 (1998), 379-382
punsarn.item.page.citation
B. Ongphiphadhanakul, N. Piaseu, L. Chailurkit, R. Rajatanavin Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover. Calcified Tissue International. Vol.62, No.5 (1998), 379-382. doi:10.1007/s002239900448 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18300
Research Projects
Organizational Units
Authors
Journal Issue
relationships.isThesisOf
item.page.dc.title
Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover
item.page.dc.contributor.author
item.page.dc.contributor.other
item.page.dc.description.abstract
In the present study, we assessed the ability of increasing doses of intranasal calcitonin to suppress urinary deoxypyridinoline cross-link (DPD), a specific biochemical marker of bone resorption, in early postmenopausal women. Subjects consisted of 30 healthy Thai women within 5 years of postmenopause, randomly assigned to 50, 100, or 200 IU of intranasal calcitonin 5 days/week for 3 months. Calcium supplementation by calcium carbonate capsules at 750 mg of elemental calcium per day was given to all subjects. Twenty four-hour urine for DPD and creatinine assays was collected at baseline, 1 month, and 3 months after treatment. All DPD values were corrected with urinary creatinine before analyses. Data were expressed as mean ± SEM. DPD decreased significantly 1 month after intranasal calcitonin treatment (P < 0.01). However, at 3 months, DPD increased when compared with the values at 1 month (P < 0.01), suggesting that there may be a reduction in the suppression of bone resorption after prolonged calcitonin therapy. Using a stepwise multiple regression model to address whether dosage and DPD at baseline influence the response to intranasal calcitonin, it was found that DPD suppression after intranasal calcitonin was not related to dosage but was strongly associated with baseline DPD (P < 0.0001). Suppression of bone resorption in early postmenopausal women by intranasal calcitonin is determined more by the state of bone turnover at baseline than the dosage of calcitonin.
